BETA vs GUJTHEM: Stock Comparison

Beta Drugs Ltd vs Gujarat Themis Biosyn Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Gujarat Themis Biosyn Limited is the larger company by market capitalisation. Beta Drugs Ltd shows a lower P/E, a higher ROE and a higher ROCE, while Gujarat Themis Biosyn Limited shows a higher dividend yield, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Beta Drugs Ltd and Gujarat Themis Biosyn Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BETA is more favourable on 6 of 13 scored metrics and GUJTHEM on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
GUJTHEM is the larger company
₹3,926 Cr vs ₹2,558 Cr
P/E Ratio
BETA has a lower P/E
57.18x vs 84.23x
P/B Ratio
BETA has a lower P/B
9.69x vs 13.65x
EPS
BETA has higher earnings per share
₹40.9 vs ₹4.27
Dividend Yield
GUJTHEM has a higher dividend yield
0.18% vs 0%
Revenue Growth (TTM YoY)
GUJTHEM has faster revenue growth
17.2% vs 0%
EPS Growth (TTM YoY)
BETA has faster EPS growth
0% vs -9.1%
Qtr Sales Growth
GUJTHEM has stronger quarterly sales growth
17.2% vs 0.21%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBETAGUJTHEM
SectorHealthcare
IndustryPharmaceuticals

Price

MetricBETAGUJTHEM
Live Price₹2,315.6₹360.5
Day Change1.69%1.18%
Volume19,16432,351
52-Week High₹2,674₹479
52-Week Low₹990.1₹225.05
Distance from 52W High-13.4%-24.74%

Valuation

MetricBETAGUJTHEM
Market Cap₹2,558 Cr₹3,926 Cr
P/E Ratio57.18x84.23x
P/B Ratio9.69x13.65x
EPS₹40.9₹4.27
Book Value₹241₹26.41
Dividend Yield0%0.18%

Growth

MetricBETAGUJTHEM
Revenue Growth (TTM YoY)0%17.2%
EPS Growth (TTM YoY)0%-9.1%
Qtr Sales Growth0.21%17.2%
Qtr Profit Growth-15.2%-9.25%

Profitability & Leverage

MetricBETAGUJTHEM
ROE18.8%17.4%
ROCE19.2%17.9%
Net Margin10.78%28.15%
Operating Margin19.7%45.6%
Debt to Equity0.6x0.56x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBETAGUJTHEM
Promoter Holding59.1% 5.53 pp70.86%
FII Holding1.02% 0.14 pp1.8% 0.16 pp
DII Holding6.23% 4.08 pp1.18% 0.01 pp
Public Holding33.65% 1.59 pp26.16% 0.16 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Beta Drugs Ltd and Gujarat Themis Biosyn Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.